A Phase I/II Study of HE3235 in Patients With Prostate Cancer

ClinicalTrials.gov ID: NCT00716794

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00716794. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 3:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/II, Open-Label, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Activity of HE3235 When Administered Orally to Patients With Prostate Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a phase I/II, open-label, dose escalation study of HE3235 administered orally to patients with advanced prostate cancer who have failed hormone therapy and at least one taxane based chemotherapy regimen.

Study identification

NCT ID: NCT00716794
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Harbor Therapeutics; Industry
Enrollment: 64 participants

Conditions and interventions

Conditions

Prostate Cancer

Interventions

HE3235 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 2008 (Type not available)
Primary completion: Mar 2011 (Actual)
Completion: Mar 2011 (Actual)
Last update posted: Mar 9, 2011

2008 – 2011

United States locations

U.S. sites: 8
U.S. states: 6
U.S. cities: 8

Facility	City	State	ZIP	Site status
Not listed	Scottsdale	Arizona	85260	—
Not listed	Encinitas	California	92024	—
Not listed	Roseville	California	95661	—
Not listed	San Francisco	California	94115	—
Not listed	New York	New York	10065	—
Not listed	Charlotte	North Carolina	28204	—
Not listed	San Antonio	Texas	78229	—
Not listed	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00716794, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 9, 2011 · Synced Nov 13, 2026